JNJ's 62-year streak of dividend growth, 3.4% yield, and disciplined capital allocation make it highly attractive for ...

Seven pharmaceutical giants with a presence in New Jersey have announced billions in expansions. The timing is no surprise, health care analysts say.

A new book shows how Johnson & Johnson has pushed misleading narratives and suppressed inconvenient findings to sell its ...

Leveraging computerized maintenance management systems software can enhance efficiency, improve quality control, ensure ...

As such, "the combination of T-DXd and pertuzumab may represent a new first-line standard of care for patients with ...

Vepdegestrant, an investigational estrogen receptor (ER) degrader, known as a proteolysis-targeting chimera (PROTAC ), ...

But this doesn’t mean that any alternative is necessarily better. Some are proving to be demonstrably worse. J. D. Vance ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

New Brunswick, New Jersey-based Johnson & Johnson (JNJ) primarily focuses on drug discovery and manufacturing but has a ...

CHICAGO -- Combining pembrolizumab (Keytruda) with sacituzumab govitecan (SG, Trodelvy) instead of chemotherapy as first-line ...

This browser is no longer supported at MarketWatch. For the best MarketWatch.com experience, please update to a modern browser.

The payments have raised concerns that doctors could be influenced to favour specific drugs or prescribe them over talking ...